OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Dean on Remaining Challenges in DLBCL

November 19th 2020

Robert M. Dean, MD, discusses remaining challenges in diffuse large B-cell lymphoma.

Dr. Lin on the Importance of Biomarker Research in Prostate Cancer

November 19th 2020

Daniel W. Lin, MD, discusses the importance of biomarker research in prostate cancer.

Dr. Eng on Contraindications for Oxaliplatin-Based Therapy in CRC

November 19th 2020

Cathy Eng, MD, FACP, FASCO, discusses contraindications for oxaliplatin-based therapy in colorectal cancer.

Dr. Bekaii-Saab on Improved Sequencing Strategies in HCC

November 19th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses improved sequencing strategies in hepatocellular carcinoma.

Dr. Skarbnik on Current Treatment Strategies Making Waves in MCL

November 19th 2020

Alan P. Z. Skarbnik, MD, discusses treatment strategies for patients with mantle cell lymphoma.

Dr. Ayers on Recent Developments in CLL

November 19th 2020

Emily C. Ayers, MD, discusses recent developments in chronic lymphocytic leukemia.

Dr. Greene on the Future of Personalized Therapy in Prostate Cancer

November 19th 2020

Kirsten L. Greene, MD, MAS, FACS, discusses the future of personalized therapy in prostate cancer.

Dr. Janjigian on the Importance of Biomarker Testing in GI Cancers

November 19th 2020

Yelena Y. Janjigian, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of biomarker testing in gastrointestinal cancers.

Dr. Eng on the Role of Preventive Screening in CRC

November 19th 2020

Cathy Eng, MD, FACP, FASCO, discusses the role of preventive screening in colorectal cancer.

Dr. Brody on the Potential Role for Bispecific Antibodies in MCL

November 18th 2020

Joshua Brody, MD, discusses the potential role for bispecific antibodies in mantle cell lymphoma.

Dr. Winter on the Utility of PI3K Inhibitors in CLL

November 18th 2020

Allison Winter, MD, discusses the utility of PI3K inhibitors in chronic lymphocytic leukemia.

Dr. Randall on Unmet Needs in Platinum-Resistant Ovarian Cancer

November 17th 2020

Leslie M. Randall, MD, MAS, discusses the unmet needs in platinum-resistant ovarian cancer.

Dr. Subramanian on the Potential Utility of Dostarlimab in Previously Treated NSCLC

November 17th 2020

Janakiraman Subramanian, MD, discusses the potential utility of dostarlimab in previously treated patients with non–small cell lung cancer.

Dr. Ramalingam on Limitations With Immunotherapy in NSCLC

November 17th 2020

Suresh S. Ramalingam, MD, FASCO, discusses limitations with immunotherapy in non–small cell lung cancer.

Dr. Awan on the Importance of Risk Stratification in CLL

November 17th 2020

Farrukh Awan, MD, discusses the importance of risk stratification in chronic lymphocytic leukemia.

Dr. El Chaer on the Limitations of JAK Inhibitors in Myelofibrosis

November 17th 2020

Firas El Chaer, MD, discusses the limitations of JAK inhibitors in myelofibrosis.

Dr. Cavnar on the Roles of Chemotherapy and Surgery in Metastatic CRC

November 17th 2020

Michael J. Cavnar, MD, discusses the roles of chemotherapy and surgery in metastatic colorectal cancer.

Cancer Experts Spotlight the Significance of the Institutional Perspectives in Cancer Webinars

November 17th 2020

The Institutional Perspectives in Cancer webinars assemble academic and community-based physicians and healthcare professionals across key disciplines, ranging from medical to surgical oncology.

Dr. Ayers on Unmet Needs in CLL

November 16th 2020

Emily C. Ayers, MD, discusses unmet needs in chronic lymphocytic leukemia.

Dr. Brar on the Rise of New Treatment Approaches in HCC

November 16th 2020

Gagandeep Brar, MD, discusses the rise of new treatment approaches in hepatocellular carcinoma.